H1N1 Vaccine With Adjuvant Would Need Twice The Follow-up, FDA Recommends
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Vaccines and Related Biological Products Advisory Committee meets July 23 to discuss clinical trials for vaccines against the 2009 H1N1 flu virus.
You may also be interested in...
US FDA COVID-19 Adcom: What Additional Members Are Needed?
Beyond vaccine experts, specialists in medical areas where there might be safety concerns, as well as epidemiologists, could be helpful to aid the FDA in understanding the data in a coronavirus vaccine application.
Two-Dose H1N1 Vaccination Might Be Optimal, But Would Stress Supply
An FDA panel said the H1N1 flu vaccine should be given in two doses when the probable vaccine campaign starts in the fall, but government officials at the meeting said there will not likely be enough vaccine available at that point to follow that advice
Two-Dose H1N1 Vaccination Might Be Optimal, But Would Stress Supply
An FDA panel said the H1N1 flu vaccine should be given in two doses when the probable vaccine campaign starts in the fall, but government officials at the meeting said there will not likely be enough vaccine available at that point to follow that advice